Glyburide-d3

Glyburide-d3

• CAS Number: 1219803-02-7
• UNSPSC Description: Glyburide-d3 is the deuterium labeled Glibenclamide. Glibenclamide (Glyburide) is an orally active ATP-sensitive K+ channel (KATP) inhibitor and can be used for the research of diabetes and obesity[1]. Glibenclamide inhibits P-glycoprotein. Glibenclamide directly binds and blocks the SUR1 subunits of KATP and inhibits the cystic fibrosis transmembrane conductance regulator protein (CFTR)[3]. Glibenclamide interferes with mitochondrial bioenergetics by inducing changes on membrane ion permeability[4]. Glibenclamide can induce autophagy[5].
• Target Antigen: Autophagy; CFTR; Mitochondrial Metabolism; P-glycoprotein; Potassium Channel
• Type: Isotope-Labeled Compounds
• Related Pathways: Autophagy;Membrane Transporter/Ion Channel;Metabolic Enzyme/Protease
• Field of Research: Metabolic Disease
• Purity: 99.24
• Solubility: 10 mM in DMSO
• Smiles: O=C(NCCC1=CC=C(S(=O)(NC(NC2CCCCC2)=O)=O)C=C1)C3=CC(Cl)=CC=C3OC([2H])([2H])[2H]
• Molecular Weight: 497.02
• References & Citations: [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. |[2]Fernandes MA, et al. Glibenclamide interferes with mitochondrial bioenergetics by inducing changes on membrane ion permeability. J Biochem Mol Toxicol. 2004;18(3):162-169.|[3]Heo R, et al. The anti-diabetic drug trelagliptin induces vasodilation via activation of Kv channels and SERCA pumps. Life Sci. 2021;283:119868.|[4]Qiu Y, et al. Glyburide Regulates UCP1 Expression in Adipocytes Independent of KATP Channel Blockade. iScience. 2020;23(9):101446.|[5]Golstein PE, et al. P-glycoprotein inhibition by glibenclamide and related compounds. Pflugers Arch. 1999;437(5):652-660.|[6]Zhou J, et al. Glibenclamide-Induced Autophagy Inhibits Its Insulin Secretion-Improving Function in β Cells. Int J Endocrinol. 2019;2019:1265175.
• Shipping Conditions: Room Temperature
• Storage Conditions: -20°C, 3 years; 4°C, 2 years (Powder)
• Clinical Information: No Development Reported